RA CAPITAL MANAGEMENT, L.P. purchased $1.7M of COAG (indirect holdings)
RA CAPITAL MANAGEMENT, L.P. purchased 67,669 indirectly-held shares of Hemab Therapeutics Holdings, Inc. (COAG) at an average of $24.97 ($24.89–$24.98, $1.69M total) across 2 trades over 2026-06-15 to 2026-06-16.
How this was made
The 30-second read
Why it matters
RA Capital Management reported open-market purchases with no 10b5-1 plan stated, increasing its indirect holdings to 6,444,637 shares.
Market read
This is a fresh ownership-change datapoint that may modestly support sentiment, but it does not introduce new operational or clinical information.
What to watch
Because the trades were executed days earlier (6/15–6/16) and there’s no accompanying company update, the market may already have priced in any sentiment effect.
Background
The article is an SEC Form 4 insider/10% owner transaction disclosure for Hemab Therapeutics Holdings, Inc. (COAG).
Ticker impact
RA Capital Management, a 10% owner, bought 67,669 Hemab Therapeutics shares in open-market trades totaling about $1.69M at ~$24.97.
Likely limited near-term impact; any effect would be sentiment/positioning rather than a re-rating catalyst.
Form 4 shows size ($1.69M) and price range, but no new company-specific operating/regulatory/clinical information is disclosed.
Market effects
No sector-level read-through; this is a single-issuer ownership transaction.
None indicated.
None indicated.
Counterpoint
Large-holder buying on Form 4 can reflect portfolio rebalancing or indirect fund flows rather than a bullish thesis on near-term fundamentals.
Key entities
- issuerHemab Therapeutics Holdings, Inc.
COAG, the company whose shares were purchased; Form 4 reports the transaction details.
- 10% ownerRA Capital Management, L.P.
Reported open-market purchase of COAG shares totaling ~$1.69M across two trades.
